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Objective: The prevalence of aortic valve stenosis increases with age, and often the
diagnosis is made by echocardiography before symptoms develop. To address the
controversies in management of asymptomatic patients with severe aortic stenosis,
we assessed the early and late outcomes of aortic valve replacement in these patients.
Methods:We analyzed data of 622 patients, aged 726 11 years, with isolated asymp-
tomatic severe aortic stenosis. Patients were identified with a peak systolic velocity of
greater than 4 m/s by transthoracic echocardiography and monitored for the develop-
ment of symptoms and need for aortic valve replacement.
Results: After the initial diagnosis, 166 (27%) patients who were initially asymptom-
atic experienced the development of chest pain, shortness of breath, or syncope and
had aortic valve replacement at Mayo Clinic. Another 97 (16%) patients had aortic
valve replacement in the absence of symptoms. Symptomatic patients were more
likely to undergo coronary bypass grafting (P, .01) and have diabetes, hypercholes-
terolemia, and a lower ejection fraction (P , .05 for each). Operative mortality was
2% for symptomatic patients and 1% for asymptomatic patients (P 5 .43). The sur-
vival of the 263 patients who underwent aortic valve replacement was not signifi-
cantly different from an age- and sex-matched population (P 5 .99); 10-year
survival was 64% (95% confidence interval [CI] 57%–72%) for symptomatic patients
and 64% (95% CI 54%–75%) for asymptomatic patients (P 5 .92). At 3 years after
diagnosis of severe aortic stenosis, 52% (95% CI 48%–56%) of 622 patients had
had symptoms develop, undergone aortic valve replacement, or died. Among the en-
tire cohort, older age at diagnosis (hazard ratio [HR] 1.1 per year, P, .001), diabetes
(HR 1.7, P , .001), decreased ejection fraction (HR 1.1 per 1%Y, P 5 .01), symp-
toms (HR 2.13, P , .001), and absence of aortic valve replacement (HR 3.53, P ,
.001) were identified as independent risk factors for mortality.
Conclusion: Among patients with severe aortic stenosis who underwent aortic valve
replacement, early and late outcomes were similarly good in patients who had symp-
toms before the operation compared with those who were asymptomatic. It is impor-
tant to note that among patients with asymptomatic severe aortic stenosis, the
omission of surgical treatment was the most important risk factor for late mortality.
I
n 1965, McGoon, Pestana, and Moffitt1 wrote about aortic valve replacement
(AVR), ‘‘Low hospital mortality tends to justify a policy of accepting patients
for operation earlier in the natural progression of their disability, because it is rec-
ognized that there is a definite risk of rapid deterioration or sudden death in the earlier
policy of deferring operation.’’ Forty years later, management of asymptomatic
patients with aortic valve stenosis (AS) remains a dilemma for cardiologists and
surgeons. Traditionally, patients with asymptomatic severe AS are monitored expec-
tantly until the development of symptoms because of the perceived low risk of sudden
death.2 In these natural history studies, most patients were younger than those encoun-
tered by clinicians today and patients were more likely to have underlying bicuspid
aortic valve disease. This approach also depends on satisfactory follow-up and prompt
identification of the onset of symptoms.
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Decreasing surgical mortality for AVR and technological
advancements in aortic valve prostheses argue for earlier sur-
gical referral for most patients with aortic valve disease. A
previous study of asymptomatic severe AS from the Mayo
Clinic concluded that symptoms will develop within 5 years
in most patients and that sudden death occurs at a rate of ap-
proximately 1% per year.3 In the present investigation, we
compared late survival in patients with asymptomatic severe
AS who were followed up medically versus patients who
underwent AVR. In addition, we compared late outcomes
of patients who had AVR in the presence of symptoms
with those who remained asymptomatic at the time of AVR.
Materials and Methods
Approval for this study was granted by our institutional review
board, and all patients gave written consent. We studied a cohort
of 622 patients who had isolated asymptomatic AS,3 defined as
a peak systolic velocity of 4 m/s or greater by Doppler echocardiog-
raphy. We excluded patients with any symptoms, age 40 years or
younger, and those with multivalvular disease or moderate-to-se-
vere aortic valve regurgitation. Other exclusion criteria included
previous aortic balloon valvuloplasty, history of myocardial infarc-
tion, and prior coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty.
All 622 patients were entered into the study between 1984 and
1995 at the time of echocardiographic diagnosis of severe AS. Echo-
cardiographic data included peak aortic valve velocity, aortic valve
area, and the presence of left ventricular hypertrophy. As well, inac-
tive status (assisted care) or active status (independent living) was
recorded. After the initial diagnosis of severe AS, patients were ad-vised to return every 6 months to 1 year for re-evaluation. By re-
viewing of medical records, mailed questionnaires, and scripted
telephone interviews, information regarding the development of car-
diac symptoms, aortic valve surgery, and mortality were obtained
for all patients. Death was confirmed by a death certificate or the So-
cial Security Death Index.
Of the 622 patients initially identified, 297 had symptoms de-
velop during follow-up (Figure 1), and 207 of these symptomatic pa-
tients underwent AVR. An additional 145 patients had AVR in the
absence of symptoms. Of these patients who underwent AVR, 166
symptomatic patients and 97 asymptomatic patients had surgery at
Mayo Clinic. This group of 263 patients had preoperative and intra-
operative variables collected including a history of smoking, diabe-
tes, hypercholesterolemia, renal failure (creatinine level . 2.0 mg/
dL), hypertension, stroke, endocarditis, chronic lung disease, myo-
cardial infarction, preoperative arrhythmia, preoperative ejection
fraction, and cardiogenic shock. All preoperative and intraoperative
characteristics were defined by The Society of Thoracic Surgeons
Adult Database definitions.
Only patients who had AVR at the Mayo Clinic were included in
the analysis of early and late operative outcomes because for these
patients, all perioperative data were available. In the larger compar-
ison of operative versus nonoperative groups, we included longitu-
dinal data for all patients having surgery including those who had
valve replacement at other institutions because vital status of all pa-
tients was known.
All statistical analyses were performed with SAS software (ver-
sion 9.1.3; SAS Institute, Inc, Cary, NC). Data are summarized as
means and standard deviations or frequencies and percentages.
Groups were compared by t tests and c2 tests as appropriate. Sur-
vival was analyzed by the Kaplan–Meier method, and survival
curves were compared by the log–rank test. Also, survival of pa-
tients after AVR was compared with that of the Minnesota popula-
tion matched for age and sex and tested by the 1-sample log–rank
test. Cox proportional hazards regression was used to identify vari-
ables independently associated with survival end points. Multivari-
ate Cox models were formed by stepwise selection techniques.
Estimated hazard ratios and 95% confidence intervals from models
are presented.
To determine survivorship of all patients, we used the date of di-
agnosis of severe AS as time zero. Development of symptoms andFigure 1. Follow-up of patients diagnosed with
asymptomatic severe aortic stenosis.
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sion analysis. Figures showing survival for AVR and symptom
groups were created by allowing patients to be in one or more of
the curves. Patients were not allowed to be in multiple curves at
the same time and could transfer into different curves on the basis
of their AVR and symptom status at any time.
In the second analysis of only patients who had AVR, time zero
was the date of surgery, and patients were censored if lost to follow-
up. Cox models were used to predict late survival after the operation
using patient characteristics at time of surgery.
Results
Demographics
Six-hundred twenty-two asymptomatic patients were identi-
fied by echocardiography as having severe AS. The mean pa-
tient age at diagnosis was 726 11 years, and 384 (62%) were
men. The mean peak velocity was 4.4 6 0.4 m/s and mean
aortic valve area was 0.96 0.2 cm2. The mean ejection frac-tion was 64.3% 6 7.3%. For the entire group, follow-up
averaged 7.8 6 5.3 years.3
Among these patients, 263 subsequently underwent AVR
at Mayo, and the mean postoperative follow-up time was 9.1
years (64.7 years). Comparing the asymptomatic and symp-
tomatic patients who underwent AVR, there were no signif-
icant differences in age, gender, body mass index, and body
surface area between the groups (Table 1) at the time of sur-
gery. The mean length of time from diagnosis of asymptom-
atic severe AS to AVR was longer in the symptomatic
patients (2.38 6 1.7 years vs 1.94 61.7 years; P 5 .04).
Both aortic peak velocity and aortic valve area were similar
in the two groups. Although most cardiovascular risk factors
were not significantly different between asymptomatic and
symptomatic patients, there was a higher prevalence of diabe-
tes and hypercholesterolemia in the symptomatic patients.
In the symptomatic AVR group, there were significantly
more patients who required concomitant coronary arteryTABLE 1. Demographics of patients at time of AVR
Variable Asymptomatic (n 5 97) Symptomatic (n 5 166) P value
Mean age at surgery 68.9 6 8.5 71.1 6 10.5 .08
Male gender, No. (%) 60 (62%) 114 (69%) .26
Mean body mass index (kg/m2) 26.7 6 3.8 27.3 6 4.4 .22
Mean body surface area (m2) 1.91 6 0.2 1.94 6 0.3 .37
Smoker, No. (%) 43 (44%) 72 (43%) .88
Diabetes, No. (%) 4 (4%) 21 (13%) .02
Hypercholesterolemia, No. (%) 30 (31%) 75 (45%) .02
Renal failure, No. (%) 3 (3%) 1 (1%) .11
Hypertension, No. (%) 49 (51%) 85 (41%) .91
Cerebral vascular accident, No. (%) 9 (9%) 9 (5%) .23
Infectious endocarditis, No. (%) 0 (0%) 4 (2%) .12
Chronic lung disease, No. (%) 5 (5%) 18 (11%) .12
Myocardial infarction, No. (%) 4 (4%) 12 (7%) .31
Cardiogenic shock, No. (%) 0 (0%) 1 (1%) .44
IABP, No. (%) 2 (2%) 3 (2%) .88
Preoperative arrhythmia, No. (%) 20 (21%) 44 (27%) .27
LVH by ECG, No. (%)* 19 (20%) 32 (19%) .95
Aortic valve area (cm/m2)* 0.87 6 0.2 0.90 6 0.3 .50
Peak velocity (m/s2)* 4.37 6 0.4 4.30 6 0.4 .14
Mean ejection fraction (%) 63 6 8.9 60 6 12.5 .04
Tricuspid aortic valve, No. (%) 41 (42%) 104 (63%) ,.01
Coronary bypass graft, No. (%) 26 (27%) 76 (46%) ,.01
Mean cross-clamp time (min) 58.8 6 23.2 65.9 6 26.7 .03
Mean CPB time (min) 86.4 6 33.5 96.5 6 39.7 .04
Length of time to AS Dx at surgery 1.94 6 1.7 2.38 6 1.7 .04
Valve type
Bioprosthetic 53 (55%) 83 (50%)
Mechanical 42 (43%) 73 (44%) .47
Homograft 1 (1%) 7 (4%)
Decalcification procedure 1 (1%) 3 (2%)
Operative mortality, No. (%) 1 (1%) 4 (2%) .43
AS, Aortic stenosis; AVR, aortic valve replacement; CPB, cardiopulmonary bypass; Dx, diagnosis; ECG, electrocardiogram; IABP, intra-aortic balloon pump;
LVH, left ventricular hypertrophy. *Characteristics of patients at time of entry into study.
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and crossclamp times. There were greater numbers of pa-
tients in the asymptomatic AVR group who had bicuspid or
unicuspid aortic valves, whereas most patients had tricuspid
aortic valves in the symptomatic group. In each group, there
were similar proportions who received stented bioprosthetic,
mechanical, and homograft replacement valves.
Survival of Patients Stratified on Symptom
Status and AVR
After 3 years of follow-up, 52% (95% confidence interval
[CI] 48%–56%) of 622 patients had had symptoms, had
undergone AVR, or had died (Figure 2). Survival of all
622 patients who were originally given the diagnosis of
asymptomatic severe AS is shown in Figure 3. Patients
Figure 2. The probably of death, aortic valve replacement, or symp-
toms in patients diagnosed with asymptomatic aortic stenosis.were also stratified into those who did and did not have
symptoms and those who did and did not undergo AVR.
Patients who had symptoms but did not have AVR had
a 10-year survival of 2% (95% CI 1%–6%). In patients
who remained asymptomatic and did not have AVR, 10-
year survival was only 33% (95% CI 24%–45%). In pa-
tient in whom symptoms developed and who had AVR,
10-year survival was 62% (95% CI 54%–72%), and in
those who were asymptomatic but had AVR, survival
was 70% (95% CI 61%–80%). This analysis included all
AVR patients, both those who had operation at Mayo
and those who had operation elsewhere. By univariate
analysis, an AVR in an asymptomatic patient was protec-
tive of late death by a relative risk of 0.38 (95% CI 0.27–
0.55; P , .001). Among all 622 patients with asymptom-
atic severe AS, univariate predictors of mortality were
older age at diagnosis, female gender, hypertension, diabe-
tes, chronic renal failure, and symptom development
(Table 2).
Multivariable Predictors of Survival
Older age at diagnosis, diabetes, inactive status, decreased ejec-
tion fraction, development of symptoms, and absence of AVR
were all independent predictors of late mortality (Table 3).
Survival After AVR
Among patients who had AVR at Mayo, overall early mortal-
ity (within 30 days of surgery) was 2%. There were more
operative deaths among symptomatic patients (2% vs 1%),
but this small difference was not statistically significant (P5
.43). For all 263 patients undergoing AVR, regardless of
symptom status, survival at 5 years was 85% (95% CI
81%–90%), at 10 years, 64% (95% CI 58%–70%), and at
15 years, 36% (95%CI 28%–45%) (Figure 4).Whenwe strat-
ified patients according to symptom status, there was noFigure 3. Survival of all patients diagnosed with
asymptomatic severe aortic stenosis. AVR, Aortic
valve replacement; sym, symptomatic.
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tomatic or asymptomatic at time of surgery (P 5 .929)
(Figure 5). Survival after AVR was compared with an age-
and gender-matched Minnesota population, and there was no
observed difference in late survival (P5 .99) (Figure 6). The
last two figures include patients who had AVR at Mayo and
elsewhere.
Multivariate Predictors of Survival After AVR
Independent predictors of mortality by multivariate analysis
included increasing age (hazard ratio [HR] 5 1.10 per
year; P , .001), diabetes (HR 5 1.91; P 5 .02), previous
myocardial infarction (HR 5 2.50; P 5 .002), and previous
cerebrovascular accident (HR 5 2.40 P 5 .002). Symptom
status was not a predictor of late mortality (HR 5 1.24;
P 5 .37) on univariate or multivariate analysis.
Discussion
Because of the expanding elderly population, the prevalence
of valvular disease is expected to double in the next 20 years.4
TABLE 2. Univariate predictors of late mortality in patients
with a diagnosis of asymptomatic severe AS
Variable
Hazard
ratio
Lower
95% CI
Upper
95% CI P value
Age at echo 1.086 1.073 1.099 ,.001
Male gender 0.765 0.620 0.943 .01
Hypertension 1.253 1.020 1.540 .03
Diabetes 1.950 1.447 2.626 ,.001
Current or former smoker 0.823 0.663 1.021 .08
Aortic valve velocity
$ 4.5 m/s
1.294 1.040 1.610 .02
Chronic renal failure 2.356 1.465 3.791 ,.001
Ejection fraction ([1%) 0.985 0.970 1.001 .06
Inactivity 3.158 2.222 4.488 ,.001
Aortic valve area (cm2) 0.511 0.245 1.068 .07
Time-dependent symptoms 1.482 1.188 1.849 ,.001
Time-dependent AVR 0.274 0.212 0.355 ,.001
AS, Aortic stenosis; AVR, aortic valve replacement; CI, confidence interval.
Only variables that had a P value of ,.10 were included in this table.
TABLE 3. Multivariate model predicting late mortality in
patients with a diagnosis of asymptomatic severe AS
Variable HR
Lower
95% CI
Upper
95% CI P value
Age at diagnosis ([ 1 year) 1.07 1.056 1.083 ,.001
Diabetes 1.69 1.237 2.309 .001
EF ([ 1%) 0.98 0.963 0.994 ,.01
Time-dependent AVR 0.28 0.210 0.381 ,.001
Time-dependent symptoms 2.13 1.664 2.735 ,.001
AS. Aortic stenosis; AVR, aortic valve replacement; CI, confidence interval;
EF, ejection fraction; HR, hazard ratio.312 The Journal of Thoracic and Cardiovascular Surgery c FebStudying an elderly population, Lindroos and associates5 re-
ported a prevalence of 2.9% of severe AS. Thus, the decision
about timing of operation in asymptomatic AS is likely to be
encountered more frequently.
Some clinicians have suggested that earlier operation in
asymptomatic patients with severe AS might improve late
outcomes. Recently Pai and colleagues6 reported that survival
benefit of AVR was independent of clinical, pharmacologic,
and echocardiographic predictors. These authors recommen-
ded that the threshold for AVR in patients with severe AS
should be lowered to include asymptomatic patients.6
In our study, all patients who underwent AVR had a sur-
vival advantage compared with that of patients who remained
asymptomatic and did not undergo valve replacement. This
suggests that all patients who have severe AS, symptomatic
or not, would benefit from AVR. It is possible that some
patients who were asymptomatic may have had symptoms
develop and not told their physicians. Such patients may
have been misclassified as asymptomatic, although it should
be noted this is a potential hazard of ‘‘watchful waiting’’ and
this cannot be assessed retrospectively.
We examined the last contact (survey, telephone, or
in-person visit) in patients who eventually died while still
asymptomatic; the average time from last contact to death
was 1.7 6 2.1 years (median 0.8 years), 37% had contact
within 6 months of death, and 56% had contact within
1 year of death. Although it is possible that closer follow-
up may be beneficial, more than 50% of patients had been
contacted within 1 year of their death. Thus, patients who
are willing and have a reasonably low risk of operation
should be offered early surgery.
It is unclear in this retrospective study as to why patients
did not have an AVR in the presence of symptoms. Although
some may have not been referred, many others were elderly
and frail or had serious comorbidities such as cancer or
dementia and refused surgery.
Figure 4. Survival after aortic valve replacement.ruary 2008
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in which AVR can be safely postponed. However, when we
examined the analysis of freedom from symptoms, surgery,
or death in all 622 patients and censored patients at the
time symptoms developed or surgery occurred, we could
see no obvious ‘‘cut point’’ in our data. Instead, we found
that at 3 years, approximately 50% of patients will have
had symptoms develop, had AVR, or died.
Although patients who had AVR had clear survival bene-
fit compared with that of patients not treated surgically, there
was no apparent penalty for patients whose symptoms devel-
oped before surgery. In our study group, patients whose
symptoms developed before AVR had similar long-term sur-
vival compared with patients who had surgery during their
asymptomatic period. There was a trend toward a higher op-
erative mortality in symptomatic patients (2% vs 1%; P 5
.43) but this did not reach statistical significance. The trend
may be explained by higher prevalence of coronary artery
disease reflected by the increased frequency of revasculariza-
tion in this group (46% vs 27%; P 5 .002).
Some clinicians believe that patients who wait until the
development of symptoms may have an increased operative
and late mortality owing to a later stage of disease. In this se-
ries, patients were followed up regularly and were instructed
to return if any symptoms developed. It should be noted that
we had only 1 patient present for AVR in cardiogenic shock.
If there had been a greater number of patients requiring emer-
gency AVR in the symptomatic group, we may have seen an
advantage to intervention when patients were still asymptom-
atic.7 Further, it is possible that benefits of earlier operation
may be more apparent in patients with longstanding AS
who have complications such as severe left ventricular hyper-
trophy.
Previously, some cardiologists advised ‘‘cat-like observa-
tion’’ for asymptomatic patients with severe AS because of
Figure 5. Survival after aortic valve replacement dependent on
symptom status.The Journal of Thothe anticipated 2% to 3% yearly risk of prosthesis- and anti-
coagulant-related complications and the 1% yearly incidence
of death after AVR.8,9 However, when patients who had
received an AVR in our series were compared with an age-
and gender-matched Minnesota population, there was no dif-
ference in late survival, suggesting that the risk of aortic valve
prostheses–related complications and death may be overesti-
mated with the use of modern mechanical valves that require
lower anticoagulation levels and bioprosthetic valves that
have greater durability.
In this study, the unadjusted surgical mortality for AVR in
asymptomatic patients was 1%, and although asymptomatic
patients with severe AS may constitute a relatively low-risk
surgical group, some caution must be exercised when gener-
alizing our results. The Society of Thoracic Surgeons
National Adult Cardiac Surgery Database reports an unad-
justed mortality for isolated AVR of 3.5% and 5.6% for
combined AVR and coronary artery bypass grafting.10
The survival benefit of AVR in patients with asymptomatic
severe AS may apply only to centers that have sufficient vol-
ume of valve surgery so as to maintain very low operative
mortality.11
Otto12 and others13 suggest risk stratification of patients
with AS who do not have obvious symptoms using exercise
testing and measurement of brain natriuretic peptide. Other
identified risk factors for poor outcomes in patients with
asymptomatic AS include velocity of jet, rate of change
of jet velocity, functional status, and extent of aortic valve
calcification.14,15 Unfortunately, there was no attempt to
systematically risk-stratify patients in our study cohort. Sen-
sitive and objective measures of symptom development
may be beneficial to identify those patients who would gain
the most from early surgical intervention.
Figure 6. Survival after aortic valve replacement (AVR) for severe
aortic stenosis compared with age- and gender-matched Minne-
sota population.racic and Cardiovascular Surgery c Volume 135, Number 2 313
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medical management of severe AS until symptoms are well
established. It was stated in a recent editorial, ‘‘We, like
most cardiologists, no longer believe that surgery is the
most common cause of sudden death in asymptomatic pa-
tients with aortic stenosis.’’16 Results of the present study
support the idea of early intervention in patients with a diag-
nosis of severe asymptomatic AS when there is a low institu-
tional perioperative mortality. It is possible that future studies
that include risk stratification will improve patient selection
for AVR.
Conclusions
At 3 years, 52% of asymptomatic patients with severe AS had
symptoms develop, had AVR, or had died. Patients with
severe AS who present without symptoms do not have
greater operative and long-term mortalities if they undergo
elective AVR after the development of symptoms. Impor-
tantly, however, patients who had symptoms and patients
who remained asymptomatic and had AVR had a survival
advantage when compared with asymptomatic patients who
had medical management alone.
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Discussion
DrMichael A. Acker (Philadelphia, Pa). This paper is very impor-
tant. I believe its import lies not in the extraordinary low mortality,
for which the Mayo cardiac surgeons are to be congratulated, but
rather in this very careful observation of the natural history of
asymptomatic AS and also the similarities in the operative mortality
between the asymptomatic and symptomatic patients undergoing
AVR. I have three questions, which I will ask one at a time to
give you a chance to answer.
Although you showed overall survival and benefit for just getting
the valve replaced, 50% of your patients remained asymptomatic
without AVR and without death at 3 years. Did you look at this
group to determine preoperative characteristics such as the presence
of left ventricular hypertrophy, for instance, that would be predictive
of a benign course so that we do not have to operate on everyone
who has severe AS?
Dr Brown.We did not specifically look at that group of patients.
However, in a previous study, both a smaller aortic valve area and
left ventricular hypertrophy predicted symptom development in pa-
tients with asymptomatic AS.
Dr Acker. Second question: As you know, the operative mortal-
ity across the country for AVR and aortic valve and coronary bypass
surgery, according to The Society of Thoracic Surgeons database, is
not 1% and 2% but rather 3.5% for AVR alone and nearly 6% for an
AVR/coronary bypass. It is thus imperative, if one is considering
operating on the asymptomatic patient, to know the true operative
result. On the other hand, to complete that risk/benefit analysis,
one would have to know the rate of sudden death if we are going
to wait in the asymptomatic group and the factors that would predict
sudden death. Do you have some information on that?
Dr Brown. I cannot help you with the factors that will predict
sudden death; however, I can tell you that the rate of sudden death
in this cohort was approximately 1% per year. As you can see,
with an operative mortality of 1%, it is a reasonable decision to
operate in these patients.
Dr Acker. Finally, did you look at the need for coronary bypass
surgery or the ischemic burden as an independent risk factor for the
development of symptoms or long-term survival?
Dr Brown. Again, we did not specifically look at patients who
did or did not have coronary artery bypass grafting except for in
our multivariate model.
Dr Paul Kurlansky (Miami, Fla). You demonstrated very
nicely that AVR was an independent risk factor for lower mortality,
but obviously both in the symptomatic and the asymptomatic pa-
tients, the decision not to operate was based on many factors. Did
you use propensity analysis or any other method to try to match pa-
tients who did not have surgery with patients who did have surgery
to see whether you could discern other independent factors that
would have led to the decision not to operate?
In other words, it would seem as though merely waiting and
watching is not necessarily a wise decision, but that is not necessar-
ily the decision that was made. The decision not to operate may have
been a conscious one based on other risk factors that maybruary 2008
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sion not to operate is really a surrogate for other factors. I was won-
dering whether you used any statistical method to try to explore this.
Dr Brown. No, we did not use any type of statistical methods
such as propensity matching. The problem is that trying to identify
retrospectively why patients did not have surgery is always difficult,
and as mentioned, our beliefs are that there are several reasons.
Some patients are not referred, some patients are elderly and frail
and do not wish to have surgery, and some patients, of course,
have cancer or dementia, which may preclude an invasive proce-
dure.
DrWade L. Knight (Temple, Tex). I noticed from the summary
in the book that you did not include anyone in your group with an
ejection fraction less than 40%. Admittedly, that makes your statis-
tics look better in your outcomes, but I think what those of us in the
audience need to know is what do the real life group of patients look
like? Many of the people that might have been turned down for sur-
gery may have been turned down because of low ejection fractions
or high creatinine values. You are probably familiar with the article
in the December 2006 issue of The Annals of Thoracic Surgery, I
think out of Loma Linda, addressing the large percentage of patients
with AS turned down or never referred for aortic valve surgery. At
your institution, did you refuse AVR for patients with ejection frac-
tions less than 40%, or did you just not include them in this report?
Dr Brown. Just to make it clear, of the original cohort of patients
who were identified with asymptomatic AS, only 3% had an ejection
fraction of less than 50%. We did not specifically exclude any pa-
tient simply for having a low ejection fraction in our surgical series.
Dr Ahmed El Gamel (London, United Kingdom). The question
of mortality from your paper is quite clear: you have a low operative
mortality. However, one question that bothers me is the morbidity of
replacing a valve in a patient who is asymptomatic. Complications
like stroke, even if it is a minor one, will make the patient stay in
the hospital for a period of time. Have you any feeling of how
much morbidity the asymptomatic patients have experienced and
how long the hospital stay was for patients who needed readmission
for any complications after surgery?The Journal of ThoDr Brown.We do not look at specific data on the length of stay
after surgery. As was shown, the mortality after surgery is similar to
that of an age- and gender-matched population. However, you are
correct; we did not specifically look at the burden of morbidity in
a patient who receives an AVR.
DrChristopherM. Feindel (Toronto, Ontario, Canada).When
determining whether patients have symptoms or not, was there con-
sistency in obtaining a good history? I know that sounds pretty ba-
sic, but I think if you question patients you will often pick out
symptoms that, believe it or not, even the cardiologist might not
pick up.
Dr Brown. This study stretched over a long period of time, be-
ginning in 1984, and there was no systematic objective assessment
such as an exercise stress test. However, a cardiologist did review all
these patient charts to determine that this was an actual asymptom-
atic patient.
Dr A. W. Atkinson (Raleigh, NC). I think it is an interesting
study and it is sort of a negative study. It shows that symptoms do
not really predict the outcome of surgery. You would think other-
wise, that the more symptomatic patients are going to have a little
tougher time or a higher mortality, but that is not true. It seems
that it is very subjective, and I think we need to be much more de-
finitive. We have seen this with mitral valve disease; lots of asymp-
tomatic people’s ventricles are deteriorating. It has been my
impression that people are fairly asymptomatic, but a lot of these
people are not very active. They do not do a whole lot and the big-
gest thing in their life is to get surgery. We really need more objec-
tive criteria than just how the patient feels according to a telephone
call or when they visit the doctor. When they are afraid of surgery,
they are not going to have many symptoms. I think we need numbers
like Bonow’s mitral valve data, as someone mentioned, left ventric-
ular hypertrophy, pulmonary artery pressures, left atrial size, pres-
ence or absence of atrial fibrillation. There are a whole lot of
criteria that we need to put on these patients and see what they
have, when they have it, do they have it, and then I think we will
have a lot more sorting out as to when we need to operate on these
patients.racic and Cardiovascular Surgery c Volume 135, Number 2 315
